Northwestern University
northwestern.eduTotal trials
1,391
Active
289
Phase 3
51
Total enrollment
624,826
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 131 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisone | — | — | — | 10 | |||
| Naproxen 500 Mg | — | — | — | — | 2 | ||
| Enzalutamide | — | — | — | — | 2 | ||
| Abiraterone Acetate | — | — | — | — | 2 | ||
| Dupilumab | — | — | — | 3 | |||
| Methylprednisolone | — | — | 13 | ||||
| Dexamethasone | — | — | — | — | — | 4 | |
| cabergoline | — | — | — | — | 2 | ||
| Erythropoietin | — | — | — | — | 2 | ||
| Misoprostol Tabets | — | — | — | — | — | 1 | |
| botulinum toxin A | — | — | — | — | — | 1 | |
| Morphine Sulfate | — | — | — | — | — | 1 | |
| Topical EMLA cream | — | — | — | — | — | 1 | |
| Statin | — | — | — | — | — | 1 | |
| Gadavist 2Ml Solution for | — | — | — | — | — | 1 | |
| GnRH agonist/antagonist | — | — | — | — | — | 1 | |
| Ublituximab | — | — | — | — | — | 1 | |
| celecoxib | — | — | — | 5 | |||
| Duloxetine | — | — | — | — | 4 | ||
| Islet Cell Transplant | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA | — | — | — | — | — | 1 | |
| Valproic Acid | — | — | — | — | — | 1 | |
| cocoa flavanols | — | — | — | — | — | 1 | |
| Nitrate Rich Beetroot Juice | — | — | — | — | — | 1 | |
| Dronabinol | — | — | — | — | — | 1 | |
| Fresh Frozen Plasma | — | — | — | — | — | 1 | |
| Furosemide | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | 12 | ||
| Zanzalintinib | — | — | — | — | — | 3 | |
| Pemetrexed | — | — | — | 6 | |||
| Extended Release Metformin Hydrochloride | — | — | — | — | — | 2 | |
| Saline | — | — | 11 | ||||
| Alemtuzumab | — | — | — | — | 6 | ||
| bevacizumab | — | — | — | — | — | 11 | |
| carboplatin | — | — | — | — | 10 | ||
| gemcitabine hydrochloride | — | — | — | — | 5 | ||
| fluorouracil | — | — | — | — | 4 | ||
| Dacarbazine | — | — | — | — | — | 3 | |
| Afimoxifene | — | — | — | — | — | 3 | |
| lenalidomide | — | — | — | — | — | 3 |
91 more active programs hidden
Next readouts
- 2015-08-17
- 2022-06-01
- 2023-01-04
- 2023-05-23
- 2023-06-06
- 2023-10-21
- 2023-12-11
- 2024-01-24
- 2024-06-30
- 2024-08-20
Top conditions
- Pain46
- Depression43
- Breast Cancer35
- Lymphoma29
- Obesity27
- Pregnancy23
- Anxiety23
- Cancer19
Frequently asked questions about Northwestern University
- How many clinical trials does Northwestern University have on ClinicalTrials.gov?
- Northwestern University is listed as the lead sponsor on 1,391 clinical trials in ClinicalTrials.gov, 289 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Northwestern University's trials are in Phase 3?
- 51 of Northwestern University's trials are in Phase 3, spread across 131 active drug programs.
- What therapeutic areas does Northwestern University focus on?
- Northwestern University's most-studied conditions on ClinicalTrials.gov are Pain, Depression, Breast Cancer, Lymphoma, Obesity.
- When are Northwestern University's next clinical trial readouts?
- Northwestern University has 10 upcoming primary-completion readouts tracked here; the soonest is “Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia”, expected around 2015-08-17.